DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Omaxe Limited — Key licenses/regulatory approvals (Sub-para 12-Para B)

NSE 1 hr ago·17 Oct 2026, 6:57 am

Omaxe

Omaxe Limited has informed the stock exchanges that it has received certain key regulatory approvals. This development is significant as it clears a major hurdle for the company's ongoing projects and future expansion plans. The receipt of these approvals is a positive step for the real estate developer, as it removes uncertainty regarding compliance and allows the firm to proceed with its business operations without delay.

For investors, this news is a positive signal. It suggests that the company is making progress on its strategic initiatives and adhering to necessary regulatory frameworks. The clearance of these approvals can boost confidence in the company's execution capabilities and potentially support its stock performance. Investors should monitor the company's upcoming project launches and delivery schedules to gauge the impact of this regulatory clearance on its financials.